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Abstract
The skin is the largest organ in the body and is continually exposed to external stimuli,
such as chemical and environmental substances. Cutaneous toxicity can be broadly
classified according to the mechanism of onset, namely: contact dermatitis, i.e., damage
resulting from contact with a substance (irritant dermatitis, allergic contact dermatitis,
chemical burns); photosensitivity, i.e., caused by combined effects of a substance and
ultraviolet  light  (phototoxic  dermatitis,  photoallergic  contact  dermatitis);  contact
urticaria; chemical-induced acne; pigmentary disturbance; drug rash; hair disturbance;
nail disturbance; or tumor-induced. This review outlines the function and structure of the
skin, outlining characteristics of these types of cutaneous toxicity. In recent years, advances
have been made in the development of pharmaceutical  products targeting specific
molecules or genes and nanotechnology-based pharmaceutical products, raising concerns
about the onset of toxicity by novel mechanisms involving new pharmaceutical products.
Therefore, it is important to understand the basic toxicity-related changes described herein.
Keywords: cutaneous toxicity, drugs, chemicals, toxicity studies
1. Introduction
Cutaneous adverse drug or chemical reactions in patients are not common. Among hospitalized
patients, the incidence of adverse drug reactions concerning the skin ranges from 1% to 3%;
however, the actual prevalence is much higher, as many mild forms of cutaneous adverse
reactions are not reported [1]. We are constantly exposed to external stimuli, such as chemical
and environmental substances, resulting in various skin symptoms. This article focuses on (1)
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the function and structure of the skin and (2) characteristics of cutaneous toxicity of pharma-
ceutical products and chemical substances in humans and animals.
2. Function and structure of the skin
Skin is the largest organ of the body, covering the surface and accounting for approximately
15–20% of body mass. In addition to its constant barrier role, protecting the living body against
external stimuli, skin is important for maintaining the body health (e.g., through regulation
of body temperature, storage of fluids and electrolytes, and the synthesis of vitamin D) and
also acts as an important component of the immune system. As a sensory organ, the skin can
sense pain, touch, pressure, and temperature [2]. Histologically, the skin consists of the epider-
mis, dermis, and subcutaneous tissue. The epidermis is formed by keratinized squamous
epithelia, stratified from the surface into the cornified layer, clear layer (only on the palms and
soles), granular layer, spinous layer, and basal layer [3]. The epidermis also contains antigen-
presenting Langerhans cells (mainly in the spinous layer); melanocytes (mainly in the basal
layer), which produce melanin to protect epidermal cells against damage induced by ultra-
violet light; and Merkel cells (mainly on the palms and soles), which are neuroendocrine cells.
The dermis is composed of fibrous connective tissue with elastic and reticular fibers inter-
mingled with collagen bundles, containing mast cells that are involved in allergic reactions,
sweat glands, sebaceous glands, hair follicles, blood vessels, lymphatic vessels, and nerve
fibers. Subcutaneous tissue is composed of loose connective tissue and subcutaneous adipose
tissue. Adipose tissue is especially prominent in the footpads where it functions as a “shock
absorber” and as an insulating layer [4]. Skin appendages are skin-associated structures that
serve a particular function, including sensation, contractility, lubrication, and heat loss. They
contain hairs (sensation, heat loss, filter for breathing, protection), sebaceous glands (secrete
sebum onto hair follicles, which oils the hair), sweat glands (can produce sweat secreted with
strong odor (apocrine) or with a faint odor (eccrine), and nails (protection). Hair growth occurs
in three stages: anagen (growth phase), catagen (involution period), and telogen (resting phase
during which hair shedding occurs) [5, 6]. The rate of hair growth and duration of the growth
cycle vary in different areas of the body and are influenced by sex hormones and growth
factors. Sebaceous glands are most often associated with hair follicles and produce sebum by
holocrine secretion. Zymbal’s gland is a specialized sebaceous gland in rodents located at the
base of the external ear canal; the gland cells contain cytochrome P450 isoenzyme and
peroxidases and are capable of chemical metabolism [7, 8]. Apocrine glands are distributed
throughout the skin of most laboratory animals, whereas in humans they are located in axillary,
pubic, and perianal areas, while they are only present in the plantar areas in rodents. There
are a number of specialized apocrine glands, such as the anal sac gland of dogs, the ceruminous
glands of the external ear canal, and the glands of Moll in the eyelids. Eccrine glands are found
throughout the body in humans; however, these glands are limited to the footpads of
carnivores and rodents.
In preclinical studies, cutaneous toxicity is rarely encountered, except in cutaneous application,
intradermal administration, and subcutaneous administration. Cutaneous toxicity primarily
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involves either a direct local inflammatory reaction to the drug without involvement of an
immunological mechanism or an indirect inflammatory reaction associated with a systemic
manifestation [6]. In cutaneous application studies, both epidermis and skin appendages are
important factors in transdermal drug absorption [9]. Experimental animals such as guinea
pigs, monkeys, and swine exhibit similar absorption characteristics to humans [5]. Of all
laboratory animals, swine skin is most structurally comparable to human skin [4]. Swine and
humans have comparable stratum corneum, epidermal thickness, and hair follicle density, as
well as similar chemical composition of the stratum corneum. Rodents have much thinner skin
(especially the epidermis) with greater permeation compared to humans [4]. In general, skin
is thicker over the dorsal and lateral surfaces and thinnest on the ventral and medial surfaces.
Areas of skin that contact the ground, such as footpad and heels, have the thickest epidermis
(Figure 1). The extent of transdermal drug absorption differs according to skin location. Sites
in order of favorable absorption, due to the skin thickness, are the abdomen, forehead, palms,
and soles of feet [5]. It should be noted that skin thickness varies considerably during the hair
cycle (Figure 2). Skin thickness during the anagen stage is thickest and is thinnest during the
catagen stage in rodents and rabbits. If the skin is damaged, the biological protective barrier
function decreases, leading to a significant increase in drug absorption, which results in
intensified systemic toxicity [10]. Microsomal enzymes in keratinocytes are capable of metab-
olizing topically applied chemicals, thus rendering them inactive or active. Dimethyl-
benz(a)anthracene (DMBA) becomes a potent skin carcinogen after metabolic activation by
keratinocytes [11].
Figure 1. Comparative histology of different skin locations in rats. (a) Scalp region at the vertex. (b) Nose region. (c)
Inguinal region. (d) Back region. (e) Abdominal region. (f) Footpad region. (g) Eccrine sweat gland in the footpad.
Note that scalp, inguinal, and abdominal skin are thin. In contrast, back and footpad skin are thicker. Footpad skin is
the thickest, especially the stratum corneum and epidermis. Eccrine sweat glands are located only in the footpad of
rodents; however, these glands are found throughout the human body.
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Figure 2. Comparative histology of back skin during different hair cycle stages. (a) Anagen stage in the mouse. (b)
Catagen stage in the mouse. (c) Anagen stage in the rat. (d) Catagen stage in the rat. (e) Anagen stage in the rabbit. (f)
Catagen stage in the rabbit. Note that skin thickness is thickest at the anagen stage and thinnest at the catagen stage in
rodents.
3. Types of cutaneous toxicity (Table 1)
Cutaneous toxicity can be classified according to the mechanism of onset into the following: (1)
contact dermatitis, i.e., damage resulting from contact of the skin with a drug (irritant dermatitis,
allergic contact dermatitis, and chemical burns); (2) photosensitivity, caused by the combined
effect of a chemical substance and ultraviolet light (phototoxic dermatitis and photoallergic
contact dermatitis); (3) contact urticaria; (4) chemical-induced acne; (5) pigmentary disturbance;
(6) drug rash; (7) hair disturbance; (8) nail disturbance; and (9) tumor-induced. Cutaneous toxicity
can also be classified according to the route of exposure, i.e., either due to systemic effects or local
irritation of the skin (local toxicity) [5, 6].
3.1. Contact dermatitis
Contact dermatitis is skin inflammation occurring as a result of direct contact of the skin with a
drug that can be classified into the following three types, according to the mechanism of onset.
3.1.1. Irritant dermatitis
Irritant dermatitis is an inflammatory change caused by direct irritation of the skin that can be
either acute or cumulative. Activation of mast cells, complement or prostaglandin synthesis
results in reversible damage to the skin, observed as irritation within 4 hours following topical
application of the chemicals. Irritant dermatitis is characterized by inflammatory cell infiltration,
acanthosis, epidermal hyperkeratosis, and hyperplasia associated with other epidermal changes
such as erosion/ulcer, necrosis, or vesicle formation [11]. Irritant dermatitis depends on the
severity of the irritants and duration of their exposures [5, 6] (Figure 3). If the damage to the skin
is irreversible, the lesion is clinically referred to as corrosion, which is characterized by full
thickness necrosis of the epidermis penetrating into the underlying dermis [11]. In preclinical
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studies of topical application agents, skin irritation testing is conducted using rabbits or guinea
pigs to evaluate drug-induced irritation using the Draize method (with a 5-grade score based on
macroscopic assessment of the severity of erythema, crusting, and edema) (Figure 4 and Table 2).
The Draize test consists of application of the chemical to the test site on shaved dorsal skin. The
test sites undergo gross evaluation at 6, 24, and 72 postapplication.
Classification Type Definition and characteristics
A. Classification
according to the route
of exposure to the
drug
Cutaneous toxicity due
to systemic effect
Local irritation of skin
(local toxicity)
B. Classification
according to the
mechanism of onset
1. Contact dermatitis Irritant dermatitis Skin inflammation occurring as a result of direct contact of the skin
with a drug, without involvement of an immune mechanism
Allergic dermatitis Skin inflammation upon re-exposure to a drug that had been
previously administered and bound as a hapten to a protein in the
skin to become immunogenic (type IV allergic reaction)
2. Photosensitivity Phototoxic dermatitis A condition caused by a drug with covalent binding as a result of a
photochemical reaction with ultraviolet light
Photoallergic dermatitis Skin inflammation upon re-exposure to a previously administered
drug that absorbed ultraviolet light and was transformed to act as a
hapten to bind with a protein in the skin to become immunogenic
(type IV allergic reaction)
3. Contact urticaria Acute erythema with involvement of histamine release from mast
cells (increased vascular permeability), occurring soon after contact
with the drug
4. Chemical acne Inflammation of hair follicles due to excessive keratin and sebum in
hair follicles
5. Pigmentary
disturbance
Hyperpigmentation A condition occurring in association with increased melanin
production due to activation of melanocytes, hemosiderin
deposition due to hemorrhage, or deposition of the drug itself
Hypopigmentation A condition occurring in association with loss of melanin or
selective damage to melanocytes
6. Drug rash
(cutaneous reaction)
Toxic epidermal
necrolysis,
oculomucocutaneous
syndrome
The mechanism remains unknown, although an allergic reaction
has been speculated. Reported for greater than 1100 drugs,
including sulfa drugs
7. Hair disturbance Alopecia A condition due to drugs with an androgenic effect acting on hair
follicles to shorten the hair cycle, or drugs with an antimitotic effect
inducing atrophy of hair follicles and prolongation of the resting
phase of the hair cycle
Hypertrichosis A condition due to prolongation of the anagen phase of hair
follicles induced by certain immunosuppressants,
antihypertensives (minoxidil), or drugs for benign prostatic
hyperplasia (finasteride)
8. Nail disturbance Nail transverse ridges,
onycholysis,
discoloration
A condition arising from damage to the nail matrix cells due to
drugs with an antimitotic effect or deposition of the drugs
themselves
9. Tumors
This table has been modified from [5].
Table 1. Classification of drug-induced cutaneous toxicity.
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Figure 3. Sequential stages of inflammatory changes in irritant contact dermatitis following a single exposure to so-
dium lauryl sulfate (SLS) in the guinea pig. (a) Epidermal necrosis and slight infiltration of neutrophils in dermis are
observed 24 hours after exposure. (b) Epidermal necrosis and severe infiltration of neutrophils in epidermis and der-
mis are observed 24 hours after exposure. (c) Epidermal abscess (pustule) and acanthosis (epidermal regeneration) are
observed 48 hours after exposure. Owing to its emulsifying properties, SLS is an anionic surfactant used in many hy-
gienic and cleaning products, including shampoos, toothpastes, and shaving foams.
Figure 4. Macroscopic photos from a cumulative dermal irritation study in animals. (a) After the hair on the back of the
rat is shaved, the drug is continually applied to the same area. The rat wears the Elizabethan collar to prevent the ani-
mal from biting or licking the exposure site. (b) Cumulative dermal irritation study in a rabbit (left: vehicle application,
right: drug application). The site of drug application is observed with erythema, redness, swelling, and moistness. The
change spreads beyond the site of application, indicating a strong irritant property of the drug.
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Skin reaction Grading value
Erythema and eschar formation
No erythema 0
Very slight erythema (barely perceptible) 1
Well-defined erythema 2
Moderate-to-severe erythema 3
Severe erythema to slight eschar formation 4
Edema formation
No edema 0
Very slight edema (barely perceptible) 1
Slight edema (raised edges of area well defined) 2
Moderate edema (raised more than 1 mm) 3
Severe edema (raised more than a mm and extending beyond the area of exposure) 4
Eschar is scab or crust formation.
This table has been modified from [4].
Table 2. Skin irritation test (Draize scale).
3.1.2. Allergic contact dermatitis
Allergic contact dermatitis is a condition caused by a delayed (type IV) allergic reaction. A low
molecular weight drug binds as hapten to a protein in the body to act as a complete antigen.
Characteristically, inflammation is induced approximately 12 hours following recontact of a
sensitized animal with the drug. Known sensitizing substances include preservatives con-
tained in topical application agents, nickel sulfate, potassium dichromate, neomycin, aroma
chemicals, formaldehyde, rubber/latex medical supplies, and plants (e.g., rhus lacquer).
3.1.3. Chemical burns
Chemical burns are an injury caused by a chemical substance that is extremely corrosive or
irritating (e.g., strong acid or strong alkali), often involving itching and/or ulceration due to
local coagulative necrosis (Figure 5). No currently available pharmaceutical products cause
this type of injury. Accidental exposure to skin or oral ingestion of these chemicals represents
a pediatric emergency problem and these chemicals have a history of being common agents
used for suicide [12, 13]. Cement burn is well known in the developed world. The majority of
patients are either workers in the construction industry or do-it-yourself enthusiasts, com-
monly kneeling or standing in cement. The mechanism of injury is a combination of the effects
of cement alkalinity and mechanical abrasion. Besides denaturing protein, alkalis saponify fat-
producing liquefactive necrosis [14].
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Figure 5. Sodium hydroxide-induced burn in the back skin of a rat. Severe coagulative necrosis is observed in all cuta-
neous layers. Insert is a higher magnification image of the same photo.
Figure 6. Macroscopic photo from a phototoxic study of 8-methoxypsoralen in guinea pigs. After the hair on the back
of the guinea pig was shaved, the drug was applied to the same area and irradiated with ultraviolet light, and the reac-
tion was subsequently evaluated. (a) The site on the left was irradiated with ultraviolet light (UVA) after drug applica-
tion, while the site on the right was not irradiation after drug application. Erythema is observed at the site with
ultraviolet light irradiation. This reaction to 8-methoxypsoralen with ultraviolet light has been utilized in ultraviolet
light therapy (PUVA) for psoriasis in humans. (b) Apoptotic epidermal cells (sunburn cells) are observed at the site
with ultraviolet light irradiation.
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3.2. Photosensitive dermatitis
3.2.1. Photosensitivity
Photosensitive dermatitis (photosensitivity) is a general term that refers to skin inflammation
caused by the combined effect of a drug and light. It can be classified into two types, either
with or without involvement of an immunological mechanism. Numerous systemic and
topical drugs, aroma chemicals, plants, and cosmetics have been reported to induce this
condition. Some examples of photosensitizing drugs are phenothiazine, tetracyclines, sulfo-
namides, chlorpromazine, nalidixic acid, and fluorocoumarins (psoralens).
3.2.2. Phototoxic dermatitis
Phototoxic dermatitis is skin damage caused by a drug that is sensitive to light (ultraviolet
light), not by the drug alone, but after absorption of photon energy, without involvement of
an immune mechanism. Free radicals and peroxidative injuries have been reported to be
involved in this reaction. In preclinical studies of topical application agents, phototoxicity
testing is conducted using guinea pigs for evaluation of drug phototoxicity (Figure 6).
3.2.3. Photoallergic contact dermatitis
Photoallergic contact dermatitis is a condition caused by a delayed (type IV) allergic reaction.
A drug sensitive to light (ultraviolet light) absorbs photon energy and is transformed into a
substance (i.e., hapten) that combines with a protein in the body to act as a complete antigen.
Characteristically, inflammation is induced approximately 12 hours following recontact of a
sensitized animal with the drug.
3.3. Contact urticaria
Contact urticaria is acute redness or rash that occurs within several minutes to one hour
following exposure to a drug. It can be caused by a direct effect of the drug on vascular walls,
by an indirect effect on vascular walls via histamine release from mast cells (without involve-
ment of an immune mechanism), or by an IgE-mediated immediate (type I) allergic reaction
with involvement of an immune mechanism. For immune contact urticaria, known conditions
include systemic reactions to penicillin or food, as well as urticaria due to natural rubber
products (latex allergy), but it is generally difficult to reproduce such conditions in preclinical
studies using experimental animals.
3.4. Chemical-induced acne
Chemical-induced acne is a disease of hair follicles caused by a chemical substance and is
characterized by keratin plugs in hair follicles due to excessive proliferation of keratinocytes
in hair follicles (comedo), sebum retention and inflammation [11]. Known examples of
chemical-induced acne include occupational skin disorders of oil acne, caused by frequent
exposure of the skin to cutting oils, as well as chloracne, induced by dioxins such as TCDD
and PCB [15]. Clinically, the lesions are located around the eyes, ears, back, and genitalia; and
Drug-Induced Cutaneous Toxicity
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other symptoms include hyperpigmentation, conjunctivitis, and ocular discharge. A notorious
event occurred when Ukraine President Viktor Yushchenko was stricken with facial chloracne
resulting from deliberate poisoning with TCDD during his presidential campaign [16].
3.5. Pigmentary disturbance
Pigmentary disturbance is only observed in animals with scarce hair or animals that have been
shaved, thus is difficult to detect in preclinical studies. Altered pigmentation is a condition
that sometimes follows skin inflammation and is characterized histopathologically by an
increase or decrease in the number of melanocytes as well as melanin production. Hyperpig-
mentation can occur in association with increased melanin production due to drug-induced
activation of melanocytes, hemosiderin deposition due to hemorrhage, or deposition of a
heavy metal or drug itself (Figures 7 and 8). Melanin production is increased by busulfan,
cyclophosphamide, long-term high-dose ACTH, and inorganic arsenic. In addition, chlorpro-
mazine or minocycline can form a complex with melanin or hemosiderin with deposition in
the skin, leading to blue-gray discoloration of the skin. In contrast, hypopigmentation results
from loss of melanin due to damage to melanocytes. Depigmenting agents such as phenols,
catechols, and hydroquinone have a similar structure to tyrosine, thus can inhibit melanin
synthesis and induce hypopigmentation (Figure 8). Recently, an unexpected outbreak of
patients with leukoderma occurred in Japan with use of brightening/lightening cosmetics
containing rhododendrol, which is a competitive tyrosinase inhibitor, thereby inhibiting
melanin synthesis [17]. This type of leukoderma is induced by not only apoptosis of melano-
cytes but also subsequent immune reactions with CD8-positive T cell infiltration toward
melanocytes [18, 19].
Figure 7. Hyperpigmentation due to melanin deposition in dermis at a drug injection site in the monkey. (a) Crust and
epidermal hyperplasia are observed in the epidermis, and black pigment is observed in the dermis. (b) High power
field of (a). Note that the black pigment is scattered throughout the dermis.
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Figure 8. Macroscopic photo from a dermal application study of two drugs in mini-pigs (dark Yucatan pigs). The nor-
mal skin of Yucatan pigs appears black, because the skin contains a large amount of melanin pigment. With one drug
applied to the left regions of the image, darkening of the skin is shown compared to the normal portion of skin, indi-
cating excessive pigmentation due to drug application. With another drug applied to the right side of the image, light-
ening of the skin is shown with decreased pigmentation.
3.6. Drug rash (cutaneous reaction)
Drug rash (cutaneous reaction) is the most common adverse drug reaction reported to occur
with antibiotics. The most serious forms of drug rash are toxic epidermal necrolysis (TEN) and
Stevens-Johnson syndrome, which are known to occur with the use of various drugs, including
penicillin derivative or cephem derivative antibiotics, antipyretic analgesics (particularly
NSAIDs), allopurinol, amine antiepileptic drugs (phenytoin and carbamazepine), and sulfa
drugs. The Ministry of Health, Labour and Welfare of Japan announced that of 110,023 cases
of adverse drug reactions reported from 2005 to 2009, approximately 2.2% of the cases (2370)
were toxic epidermal necrolysis or Steven-Johnson syndrome [20]. Although the mechanism
of onset remains unknown in many instances, a type III allergic reaction is often speculated.
Many new antitumor drugs with specific molecular targets have been approved in recent years
(the so-called “targeted therapies”), and their adverse effects are highly specific with respect
to the skin. Cutaneous reactions to these therapies are among the most frequently observed
and, when severe or protracted, can result in significant morbidity, requiring dose modification
or drug discontinuation [21, 22]. Hyperplastic changes of the epidermis can be attributed to
numerous causes, including response to stimulation from growth factors, such as epidermal
growth factor (EGF). The repeated administration of EGF to cynomolgus monkeys results in
cutaneous desquamation and epidermal hyperplasia [23]. Epidermal growth factor receptor
(EGFR), multikinase, c-Kit, BRAF, or MEK inhibitors induce papulopustular rash, maculo-
papular rash, and hand-foot syndrome in humans [24, 25]. EGFR inhibitor-induced lesions are
associated with the inhibition of EGFR in undifferentiated, proliferating keratinocytes in the
basal and suprabasal layers of the epidermis [26]. Other inhibitor-related rashes appear to be
associated with the inhibition of vascular endothelial growth factor (VEGF) receptors in the
skin [24].
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3.7. Hair disturbance
Many drugs induce hair disorders, such as hair loss, stimulated hair growth, or, more rarely,
changes in the hair shape and color [27]. Hair loss (hypotrichosis or alopecia) is a common
problem that affects approximately 60 million men, women, and children in the United States,
with a total cost for medical consultation and treatment of US$1.3 billion per year [28]. The
onset of alopecia (toxic alopecia) often depends on the hair cycle at the time of drug adminis-
tration. Drugs with an androgenic effect can cause alopecia by acting on the resting phase of
the hair cycle to shorten the cycle. In addition, drugs with an antimitotic effect (e.g., anticancer
drugs) or irradiation can cause alopecia by inducing apoptosis of hair follicles during the
anagen phase of the hair follicle, thereby causing atrophy of hair follicles and prolongation of
the resting phase of the hair cycle (chemotherapy or radiation-induced follicular dystrophy)
[29, 30] (Figure 9). Hypertrichosis refers to drug-induced promotion of hair growth or
induction of the anagen phase [31] Figure 10, and has been reported in organ transplant
recipients and animal models treated with cyclosporine [32], as well as an antihypertensive
(minoxidil) and a drug for treating benign prostatic hyperplasia (finasteride) [33]. Minoxidil
and finasteride have been approved for clinical use as drugs to stimulate hair growth [34].
Hypertrichosis is observed as an increase in the length, thickness, and number of eyelashes in
glaucoma patients treated with prostaglandin F2α agonists [35]. Bimatoprost has been used
as a therapy for eyelash insufficiency or as eyelash restorer. As in the cases of the pigmentary
disturbances described above, these changes can only be observed in animals with scarce hair
or animals with shaved hair and are thus difficult to detect in typical preclinical studies.
Figure 9. N-Methyl-N-nitrosourea (MNU)-induced follicular dystrophy in C57BL mice. (a) Systemic hair loss and
whitening skin color are observed in the mouse treated with MNU (right side), compared to the control mouse with
abundant hair (left side). MNU is an alkylating agent used as an antimitotic chemical, and induces apoptosis of hair
follicles during the anagen phase of the hair follicle causing atrophy of hair follicles and prolongation of the resting
phase of the hair cycle. (b) Anagen stage of hair cycle in a control mouse. (c) Catagen stage of hair cycle (follicular
dystrophy) in a MNU-treated mouse. (b) and (c) are at the same magnification.
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Figure 10. Immunosuppressant drug-induced hypertrichosis in a mouse follicular dystrophy model. (a) Compared to
N-methyl-N-nitrosourea (MNU)-induced follicular dystrophy in the treated mouse (left side), the mouse treated with
the immunosuppressant drug after MNU exposure has abundant body hair (right side) (b) MNU-induced follicular
dystrophy is characterized by a prolonged catagen stage of hair cycle and thinness of the back skin. (b) and (c) are at
the same magnification. (c) The hair cycle in the mouse treated with the drug after MNU exposure was found to be in
the anagen stage with thickening of the back skin. (b) and (c) are at the same magnification.
3.8. Nail disturbance
Nail changes that reflect a previous general condition are a barometer of health that can be
used to predict the presence or absence of an abnormality several weeks before its presenta-
tion [6]. Transverse ridges (Beau’s line), washboard nail plates, and onycholysis are known to
occur with use of metoprolol, retinoids, anticancer drugs, or irradiation [5]. Adverse effects of
targeted molecular therapies, such as EGFR inhibitors, are also highly specific with respect to
nails in human patients [22, 36]. In addition, yellow nail discoloration is known to occur with
penicillamine, and black nail discoloration with Futraful (tegafur), anticancer drugs, or gold
drugs. Administration of nucleoside analogs to dogs results in nail loss and footpad erosions
with associated radiomimetic defects in the stratum germinativum [4]. In general, onycholysis
can be induced by anticancer drugs or irradiation in experimental animals, while other changes
are difficult to detect in preclinical studies.
3.9. Skin carcinogenesis
Some photoirritants, such as 8-methoxypsoralen, have been associated with UV-induced skin
carcinogenesis. Treatment of psoriasis by photochemotherapy (PUVA) with oral methoxsalen,
a psoralen, in conjunction with UVA radiation, is associated with an increased risk of irregular
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pigmented skin lesions, squamous cell carcinoma, and malignant melanoma [37, 38]. Chemi-
cally induced skin tumors have been associated with numerous topically applied and
systemically administered compounds in rodents; however, there appear to be few clinically
used drugs that are suspected of being involved in skin carcinogenesis in humans. Rodent
models of skin carcinogenesis are widely used for studies of carcinogenic mechanisms and the
evaluation of carcinogenesis associated with chemical substances. Huff et al. performed a
retrospective investigation of carcinogenicity tests on 379 chemical compounds conducted by
the US National Toxicology Program (NTP) and reported that increased skin carcinogenesis
was observed with 19 chemical compounds [39] (Table 3). Currently used methods used to
determine skin carcinogenesis of drugs/chemical substances or methods to clarify carcinogenic
mechanisms include: 2-year dermal application carcinogenicity studies (Figure 11); DMBA/
TPA two-stage skin carcinogenesis models using 12-O-tetradecanoylphorbol-13-acetate (TPA)
and 7,12-dimethylbenzanthracene (DMBA) (DMBA as an initiator, TPA as a promoter) [40];
studies in Tg.AC transgenic mice with expression of the v-Ha-ras gene in the epidermis [41];
and studies in SENCAR (SENsitivity to CARcinogen) mice [42]. Two-stage skin carcinogenesis
models using metallothionein-I/II knockout mice have shown significant increases in skin
carcinogenesis, thereby indicating an important role of metallothionein as an inhibitory factor
of carcinogenesis in skin [43]. p53 is a protein that causes cell cycle arrest, apoptosis, or
senescence that is crucial in the process of tumor suppression in several cell types [44]. In the
Figure 11. A 2-year dermal application study of a drug in CD1 mice. (a) Macroscopically, multiple reddish skin tumors
are observed on the back. (b) Histological findings are consistent with squamous cell papilloma.
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DMBA/TPA two-stage skin carcinogenesis model, the absence of p53 in stratified epithelia
leads to the appearance of a higher number of tumors that grow faster and become malignant
more frequently than tumors arising in mice with the wild type p53 genotype [45]. The
carcinogenic risk of a chemical after topical application is traditionally investigated in rats;
however, in recent years, Tg.AC mice have become a popular alternative. The skin of Tg.AC
mice is genetically initiated, thus the induction of epidermal papilloma in response to dermal
or oral exposure to a chemical agent acts as a reporter phenotype for the carcinogenicity of the
test chemical [11, 46]. The SENCAR mouse is an outbred strain (not genetically engineered)
that was selected specifically for increased skin tumor multiplicity and decreased tumor
latency in response to known dermal carcinogens [41]. A recent report described a possible
animal model for human keratoacanthoma involving a single intraperitoneal injection of 50
or 75 mg/kg N-methyl-N-nitrosourea in male Sprague-Dawley rats at 4 weeks of age [47]
(Figure 12). Keratoacanthoma is a benign tumor believed to arise from the epithelium of hair
follicles [48]. Peroxisome proliferator-activated receptor agonists have been associated with
the development of hemangiosarcomas in mice and hamsters and liposarcomas and
fibrosarcomas in rats [49].
Figure 12. Animal model for human keratoacanthoma following a single intraperitoneal injection of N-methyl-N-nitro-
sourea in a male rat.
3.10. Other cutaneous toxicity due to systemic toxicity
3.10.1. Acne formation due to anti-inflammatory analgesics
This is a common clinical adverse reaction to NSAIDs or steroids and involves proliferation of
acne bacteria leading to worsening of inflammation (steroid acne). In preclinical studies,
spontaneous interdigit inflammation may worsen in beagle dogs following NSAID adminis-
tration, eventually leading to skin ulcers in all extremities in severe cases (Figure 13).
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Name of chemical compound Route Any skin carcinogenesis (2-year
carcinogenesis study)
Mutagenicity
(Ames)
TR
No.
F344 rats B6C3F1 mice
Male Female Male Female
3-Amino-9-ethylcarbazole Dietary + + + + + 093
Benzene Oral CE CE CE CE – 289
Chloroethane Inhalation ? ? ? CE + 346
C.I. acid red 114 Drinking
water
CE CE + 405
C.I. basic red 9
monohydrochloride
Dietary CE CE CE CE + 285
C.I. Direct Blue 15 Drinking
water
CE CE – 397
2,4-Diaminoanisole sulfate Dietary + + + + + 084
3,3′-Dimethoxybenzidine
dihydrochloride
Drinking
water
CE CE + 372
3,3′-Dimethoxybenzidine-4,4′-
diisocyanate
Dietary + + – – + 128
3,3′-Dimethoxybenzidine
dihydrochloride
Drinking
water
CE CE + 390
2,4-Dinitrotoluene Dietary + + – – + 054
Fenthion Dietary – – ? – +/− 103
Glycidol Oral CE CE CE CE + 374
Nithiazide Dietary – + + ? + 146
5-Nitro-O-anisidine Dietary + + ? + + 127
Nitrofurazone Dietary ? CE – CE + 337
Rhodamine 6G Dietary ? ? – – – 364
Tris(aziridinyl)-phosphine
sulfide
Subcutaneous + + + + + 058
4-Vinyl-1-cyclohexene
diepoxide
Dermal
application
CE CE CE CE + 362
+: Positive, CE: apparent increase in incidence, ?: increased incidence but not significantly, −: negative, +/−: positive or
negative, TR No.: National Toxicology Program (NTP) study number.
This table has been modified from [39].
Table 3. Chemical compounds reported to produce skin carcinogenesis from systemic exposure (US NTP study).
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Figure 13. Nonsteroidal anti-inflammatory analgesic drug (NSAID)-induced skin lesion in a subacute toxicity study
using beagle dogs. (a) Macroscopic observation of an interdigit lesion in the foot pad. Severe swelling and ulceration
due to inflammation with local bacterial infection are observed. (b) In severe cases, the local lesions progress to skin
ulcers on all extremities (subcutaneous phlegmon).
3.10.2. Drug-induced skin atrophy
Skin atrophy can be observed with long-term, repeated use of corticosteroids due to inhibitory
effects on cell proliferation and/or fiber production, leading to decreases throughout the
epidermis, skin appendages (hair follicles, sweat glands, and sebaceous glands) and subcuta-
neous adipose tissue [50] (Figure 14). Skin atrophy is also commonly observed with systemic
exposure to anticancer drugs in preclinical studies.
Figure 14. Corticosteroid-induced cutaneous atrophy in the rat. (a) In normal rat skin, the skin is thick with large hair
shafts, sebaceous glands, and subcutaneous adipose tissue. (b) In the drug-exposed skin, the skin is thin with a severe
decrease in all cutaneous layers, skin appendages (hair follicles and sebaceous glands), and subcutaneous adipose tis-
sue.
Drug-Induced Cutaneous Toxicity
http://dx.doi.org/10.5772/64473
17
3.10.3. Skin ulcer due to peripheral circulatory insufficiency
A lesion similar to cutaneous gangrene seen in diabetic patients can be induced in monkeys
with certain drugs, and is speculated as a consequence of peripheral circulatory insufficiency
due to the involvement of a vascular disorder [5].
3.10.4. Drug-induced granulomatous reaction
Hypodermic injections of certain drugs induce granulomatous inflammation located at the
injection site, which is highly painful for the patients (Figure 15). Granulomas induced by
luteinizing hormone-releasing hormone analogues have been reported in some patients for
the treatment of prostatic cancers [51]. Histopathologically, epithelioid granulomatous in-
flammation with small vacuoles derived from the constituent ingredients of drug micro-
capsules has been observed [52]. In some patient cases, vaccinations induce granulomatous
reactions at the injection site due to specific inflammation and irritation [53]. Recently,
treatment with interferon has been associated with cutaneous granulomatous reactions and
sarcoid reactions [54].
Figure 15. Drug-induced granuloma in subcutaneous tissue of the rat. (a) Granuloma is observed in the subcutaneous
tissue. (b) Many foreign body giant cells that phagocytose lipoid materials are observed. Lipoid materials are derived
from the contents of the drug. (c) Dystrophic calcification is observed in the obsolete lesions.
4. Closing remarks
This review has outlined the types and characteristics of drug-induced cutaneous toxicity, as
well as providing descriptions of the methods of cutaneous toxicity testing required for safety
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evaluation. It should be emphasized that cutaneous toxicity of drugs or chemical substances
may appear in various forms. In recent years, advances have been made in the development
of pharmaceutical products targeting specific molecules, genes, or nanotechnology-based
pharmaceutical products. Due to the potential onset of cutaneous toxicity involving novel
mechanisms with new pharmaceutical products, it will continue to be important to understand
the basic toxic changes described here.
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